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Objective: To estimate numbers affected by a recent change in UK guidelines for statin use in primary preven-
tion of cardiovascular disease.
Method: We modelled cholesterol ratio over time using a sample of 45,151 men (≥40 years) and 36,168
women (≥55 years) in 2006, without statin treatment or previous cardiovascular disease, from the Clinical Prac-
tice Research Datalink. Using simulation methods, we estimated numbers indicated for new statin treatment, if
cholesterol was measured annually and used in the QRISK2 CVD risk calculator, using the previous 20% and
newly recommended 10% thresholds.Results:We estimate that 58% of men and 55% of womenwould be indicated for treatment by ﬁve years and
71% of men and 73% of women by ten years using the 20% threshold. Using the proposed threshold of 10%, 84% of
men and 90% of women would be indicated for treatment by 5 years and 92% of men and 98% of women by ten
years.
Conclusion: The proposed change of risk threshold from20% to 10%would result in the substantialmajority of
those recommended for cholesterol testing being indicated for statin treatment. Implications depend on the
value of statins in those at low to medium risk, and whether there are harms.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Lipid modiﬁcation guidelines for cardiovascular disease (CVD) pre-
vention recommend that patients who are deemed to be at high risk
of CVD should be prescribed statins to lower their LDL-cholesterol
(Cooper et al., 2010). In the UK, high risk is currently assessed using
10-year CVD risk equations that contain a combination of demographic
and clinical risk factors, including the ratio of total to HDL-cholesterol
(Anderson et al., 1991; Hippisley-Cox et al., 2008; Woodward et al.,
2007). Until recently, treatment was indicated if the calculated risk
score exceeds 20% (Cooper et al., 2010). In 2014 the National Institute
for Health and Care Excellence (NICE) recommended reducing the
threshold for treatment to 10% (National Institute for Health and Care
Excellence, 2014). If implemented, this decision would lead to an in-
crease in the number of individuals indicated for treatment; while it
has been suggested that millions of patients may be affected (Price,
2014; Thompson et al., 2014), estimated numbers have not been pub-
lished. We therefore evaluate cholesterol testing and associated CVDichard.stevens@phc.ox.ac.uk
rera@phc.ox.ac.uk (R. Perera).
. This is an open access article underrisk prediction, in primary prevention patients representative of those
attendingmonitoring in UK general practice, to estimate the number in-
dicated for treatment under monitoring schemes using the previous
20% and the newly recommended 10% risk thresholds. Cholesterol,
like most biochemical markers, is measured with biological variability
as well as assay variability, in the sense that two cholesterol measure-
ments on the same person will rarely give exactly the same result.
This uncertainty in cholesterol measurements will translate into uncer-
tainty in calculated CVD risk estimates. We therefore include in our
model a distinction between true CVD risk, based on underlying, usual
cholesterol ratio, and observed or estimated CVD risk, based on the
cholesterol ratio in a blood sample taken at a particular clinic visit.
Methods
Data were a sample of 45,151 men aged over 40 years and 36,168 women
aged over 55 years, without previous CVD and statin treatment, from the
Clinical Practice Research Datalink (CPRD) (CPRD, 2013). Age was restricted
to the earliest monitoring age in the NHS Health Check programme (NHS
Choices, 2014) to minimise potential cholesterol changes throughout meno-
pause (Bittner, 2009; Matthews et al., 2009). We use a random-effects model
to estimate the between-subject variation, the average rate of change over
time and its variation between individuals, and the short-term variability inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Table 1
Men and women from the Clinical Practice Research Datalink in 2006 indicated for new
statin treatmentwhen 10-year CVD risk is estimated annually with QRISK2 and compared
to threshold of 20% (previous guidelines for primary prevention). Bold font denotes those
whose true CVD risk is concordant with their estimated risk.
Years since
ﬁrst test
Cumulative number indicated
for treatment per 10,000
True CVD risk amongst those
indicated for treatment,
cumulative number per 10,000
b10% 10 to
b15%
15 to
b20%
≥20%
Men
0 4151 0 0 149 4002
1 4581 0 0 210 4371
2 4913 0 0 227 4686
3 5221 0 0 227 4993
4 5520 0 0 225 5295
5 5810 0 0 220 5590
6 6090 0 0 211 5878
7 6357 0 0 205 6152
8 6612 0 0 199 6414
9 6861 0 0 193 6667
10 7103 0 0 188 6915
Women
0 3778 0 0 103 3675
1 4152 0 0 132 4020
2 4477 0 0 139 4338
3 4801 0 0 143 4658
4 5127 0 0 143 4984
5 5463 0 0 144 5319
6 5815 0 0 151 5664
7 6178 0 0 154 6024
8 6555 0 0 158 6397
9 6938 0 0 157 6781
10 7320 0 0 151 7169
Table 2
Men and women from the Clinical Practice Research Datalink in 2006 indicated for new
statin treatmentwhen 10-year CVD risk is estimated annually with QRISK2 and compared
to threshold of 10% (new guidelines for primary prevention). Bold font denotes those
whose true CVD risk is concordant with their estimated risk.
Years since
ﬁrst test
Cumulative number indicated
for treatment per 10,000
True CVD risk amongst those
indicated for treatment,
cumulative number per 10,000
b10% 10 to
b15%
15 to
b20%
≥20%
Men
0 7167 95 1409 1484 4179
1 7468 115 1401 1487 4466
2 7709 116 1366 1464 4763
3 7935 110 1339 1421 5065
4 8150 104 1312 1370 5365
5 8352 96 1279 1319 5657
6 8540 92 1232 1273 5943
7 8721 88 1181 1239 6213
8 8891 82 1124 1212 6473
9 9050 77 1063 1185 6725
10 9199 72 1005 1150 6972
Women
0 7336 117 1957 1466 3795
1 7737 119 2034 1485 4099
2 8073 111 2043 1509 4410
3 8388 108 2004 1546 4729
4 8690 100 1936 1595 5059
5 8969 88 1843 1643 5394
6 9220 75 1727 1676 5741
7 9431 59 1591 1676 6105
8 9603 47 1428 1646 6481
9 9736 35 1244 1590 6867
10 9834 24 1044 1511 7255
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simulation methods (Stevens et al., 2010) to estimate the number of men
and women who would be indicated for new statin treatment if their cho-
lesterol was measured annually and used in the QRISK2 CVD risk calculator
(Hippisley-Cox et al., 2008), using the previous threshold of 20% and the
new threshold of 10%. We assumed annual measurement because the median
(interquartile range) time between cholesterol measurements for individuals
in our CPRD sample with more than one test was 1.02 (0.56–1.65) years. We
used estimates of within-measurement variability to model the relationship
between the observed and the underlying, usual cholesterol ratio, and hence
distinguish true CVD risk fromestimated CVD risk.We estimate the distribution
of true CVD risk amongst those with estimated CVD risk above threshold. Stata
12.1 (StataCorp, 2011) was used for all analyses.
Results
The mean (SD) age, total to HDL-cholesterol ratio and systolic blood
pressure were 60.3 (12.0) years, 4.3 (1.3) and 139 (18) mm Hg in men
and 68.5 (9.0) years, 3.8 (1.1) and 142 (19) mm Hg in women. The
prevalence of diabetes was 13.4% in men and 9.9% in women. Ap-
proximately one third of men (35.4%) and half of women (49.8%)
were non-smokers; 45.2% of men and 36.8% of women were ex-
smokers; and 19.4% of men and 13.5% of women currently smoked
(5.3%, 7.3% and 6.8% of men and 4.7%, 5.1% and 3.7% of women were
light, moderate and heavy smokers respectively, as deﬁned in QRISK2)
(Hippisley-Cox et al., 2008).
The estimated SD of the within-measurement variability in total to
HDL-cholesterol ratio was 0.37 in men and 0.23 in women: that is,
(for example) within an individual man, the measured cholesterol
ratio on any given clinic visit can vary by±0.37 (SD) or ±0.73 (normal
range) around his usual value.
On average there was little change in cholesterol ratio over time:
mean change across all men in the cohort was−0.001 (95%CI−0.004
to 0.002) per year and mean change across all women in the cohort
was 0.002 (95%CI−0.001 to 0.004) per year. However, individuals var-
ied greatly around these averages: the SD of rate of change was 0.097
per year in men and 0.090 per year in women. (Thus, for 95% of men,
rate of change lies between a 0.19 per year decrease and a 0.19 per
year increase. Similarly for 95% of women, rate of change lies between
a 0.17 per year decrease and a 0.18 per year increase.)
Table 1 shows the estimated numbers indicated for treatment per
10,000 under the assumption that cholesterol ratio ismeasured annual-
ly and that treatment is indicated if QRISK2 score exceeds 20%, as in pre-
vious guidelines. We estimate that 58% of men and 55% of women
would be indicated for treatment by ﬁve years and 71% of men and
73% of women by ten years. Table 1 also shows, in these men and
women with estimated risk above 20%, the modelled distribution of
true CVD risks; only a small number of those indicated for treatment
had true risk below 20% and none had true risk below 15%.
Table 2 shows the corresponding results, under the assumption that
treatment is indicated if QRISK2 score exceeds 10%, as recommended in
the new guidelines. We estimate that 84% of men and 90% of women
would be indicated for treatment by 5 years and 92% of men and 98%
of women by ten years. Of those indicated for treatment, few had true
risk below 10% and (data not shown) none had true risk below 5%.
Discussion
The recent change of risk threshold from 20% to 10% would result in
the substantial majority of men and women above the recommended
age for cholesterol testing being indicated for statin treatment. However,
using mathematical modelling we estimate that only a small proportion
of those indicated for treatment would be due to false positive tests,
and that these are primarily amongst those close to the threshold
whether this is at 20% or 10%.
In the absence of large randomised trials powered to compare cardio-
vascular risk assessment at different thresholds,we have used establishedmodellingmethods and data representative of routine general practice in
the UK. One limitation of these analyses is the (unlikely) assumption that
CVD risk factors other than age and cholesterol level remain constant over
time. We have also not attempted to model the complexity of individual
16 E. McFadden et al. / Preventive Medicine 70 (2015) 14–16treatment decision making, however the analyses presented here aim to
form the basis for evaluation of national monitoring strategies.
Implications depend on the value of statins in those at low to
medium risk, and whether there are harms. The extensive literature
on non-cardiovascular effects of statins has recently been reviewed
(Desai et al., 2014): the best documented harms include an increased
risk of diabetes, for example (Rajpathak et al., 2009; Sattar et al.,
2010). Recent systematic reviews (Finegold et al., 2014; Ganga et al.,
2014) found no increase in muscle problems in statin groups compared
to placebo groups across randomised trials; however two trials not in-
cluded in those reviews did ﬁnd such effects (Golomb et al., 2012;
Parker et al., 2013). Beyond actual and putative harms of treatment, it
is not known whether there are other harms associated with monitor-
ing: a harm associated with ‘labelling’ has been found for hypertension
(Hamer et al., 2010). If we accept the conclusions published by the
Cholesterol Treatment Trialists' Collaboration (Mihaylova et al., 2012)
that statins have net beneﬁt in those at low risk, then the shift to a
lower threshold corresponds to the extension of a treatment, from
which almost all middle-aged men and women stand to beneﬁt, to an
increasingly high percentage of the population.
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